Erika Rovini, co-founder
(erika.rovini@coaimed.com)

June 21st, 2022
PARKINSON’S DISEASE (PD)

- 6.1 millions patients in 2016
- > 12 millions patients in 2050

Total Costs:
- 13.9 B€/year in 2016
- 2.34 B€/year in 2050

> 1.400.000 patients
400.000 patients
### PD: CURRENT CLINICAL PRACTICE

<table>
<thead>
<tr>
<th>100+ visits/month</th>
<th>On average 3 visits/year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual assessment of motor performance</td>
<td>Latent symptoms during the visits remain undetected</td>
</tr>
<tr>
<td>Therapy adjustment by phone or after months</td>
<td>Self-reported symptoms and response to therapy changes</td>
</tr>
</tbody>
</table>
THE UNMET NEEDS

Co-Creation Workshops
Interview
Prioritization Analysis

Neurologists, Patients, Caregivers and Healthcare Professionals (50+ people)

Short time visits for patients’ complete motor evaluation
Subjectivity and variability in motor assessment
Unavailable PD patients remote monitoring
A decision support tool for diagnosis, management and follow-up in Parkinson’s disease

**THE SOLUTION • WEARNVCARE•**

Objective remote monitoring

One solution, multiple advantages

- Digitalized and objective data
- Objective remote monitoring
- Better use of the resources
THE SYSTEM

IoT-enabled wearables for data acquisition and processing

Proprietary AI-based algorithms for feature extraction and data analytics

Interoperable Cloud platform for data storage, visual dashboard

At hospital for diagnosis support and follow-up visits

Connected home for therapy adjustment
COLLABORATIONS

Sheffield Hallam University, Sheffield, UK

Institute Claude Pompidou, Nice, France

Fundació Institut Guttmann, Badalona, Spain

Eurecat Centre Tecnològic de Catalunya, Barcelona, Spain

Biomedicina Sperimentale, Università di Palermo, Italy

IRCCS Istituto Auxologico Italiano, Milano, Italy

IRCCS Istituto Scienze Neurologiche, Bologna, Italy

Ospedale Apuane, Massa, Italy

AOU Careggi, Firenze, Italy

Ospedale Santa Maria Nuova, Firenze, Italy

IRCCS Fondazione Don Gnocchi, Firenze, Italy
400+ people already tested in hospitals

CLINICAL ASSESSMENT

Excellent precision & Modularity (Err<5%, TRL 7)

CLINICAL EVIDENCE

Up to 100% accuracy in characterizing PD motor symptoms (healthy subjects vs. PD patients)

Accurate monitoring of the motor subtle changes related to change in therapy

Therapy Adjustment

>80% accuracy on PD progression (mild, moderate, advanced)

Follow Up

Clinical Evidence
# Competitors Analysis

<table>
<thead>
<tr>
<th>Feature</th>
<th>WEARncARE</th>
<th>G WALK</th>
<th>Motognosis AMSA</th>
<th>Kinesia One</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motor Symptoms</td>
<td>Bradykinesia Tremor</td>
<td>✅</td>
<td>Bradykinesia</td>
<td>Bradykinesia</td>
</tr>
<tr>
<td>Portable</td>
<td>✅</td>
<td>✅</td>
<td>✅</td>
<td>✅</td>
</tr>
<tr>
<td>Sensors and placement</td>
<td>#4 fingers; #2 wrists; #2 feet</td>
<td>✅</td>
<td>✅</td>
<td>✅</td>
</tr>
<tr>
<td>Full Body Assessment</td>
<td>✅</td>
<td>✅</td>
<td>✅</td>
<td>✅</td>
</tr>
<tr>
<td>No Spatial Constraints</td>
<td>✅</td>
<td>✅</td>
<td>✅</td>
<td>✅</td>
</tr>
<tr>
<td>Exercises #</td>
<td>15</td>
<td>3</td>
<td>10 (lab version)</td>
<td>12</td>
</tr>
<tr>
<td>Compliance to MDS-UPDRS III</td>
<td>72%</td>
<td>17%</td>
<td>28%</td>
<td>56%</td>
</tr>
</tbody>
</table>
AWARDS & NETWORK

Prizes & Awards

Innovation Award Tuscany 2021
StartUp Tuscany 2020
WMF 2022 Roadshow
Meet In Italy SUB2021

Network & Partnerships

Incubation - Acceleration

IUNIVERSIÀ DEGLI STUDI FIRENZE
Open Accelerator
PoloTecnologico
LIFESSEEDER
COAIMED
MARKET TARGET

1.4 Mln Patients in EU
118M€

650,000 Patients
Italy + Germany
55M€

122,400 Patients
11.3M€

SCALE UP
Parkinsonisms
Behaviour disorders
Cognitive decline
Clinical trials
ROADMAP, BUSINESS AND INVESTMENT MILESTONES

2014-2018

- Research projects
- Clinical prevalidation (400+ subjects tested)
- Italian patents
- Scientific publications

2020-2021

- TRL7

2022

- CoAlmed FOUNDATION
- Regulatory Plan, Manufacturing
- CE CERTIFICATION, NEW PATENT, MVP
- Research Market

2023

- Pre-Seed 200 K€
- 1st Round 1M€
- Pre-market clinical trials
- Clinical Market

2024

- 2nd Round 2M€
- Market scale up

2025

- Support to Diagnosis and Monitoring
- EU Market

WE ARE HERE
REVENUE MODEL

WEARVCARE

Training
Assistance
Warranty

CUSTOM SERVICES

Distributors, sellers

Public/Private hospitals + Research centers/ universities

8.000€

4.000€ Licence

BY 5° YEAR:
Revenues = 7.300.000€
Net Income = 3.900.000€
Gianmaria Mancioppi
Psychologist
PhD BioRobotics, CSO

Filippo Cavallo
Electronics Engineer
Prof. Bioengineering, Adv

Erika Rovini
Biomedical Engineer
PhD BioRobotics, CTO

Laura Fiorini
Biomedical Engineer
PhD BioRobotics, COO

Manuele Bonaccorsi,
PhD Innovation Technology,
CEO

CLINIC ADVISORY BOARD

Dr. Carlo Maremmani
Ospedale Apuane (MS)

Dr. Silvia Ramat
Parkinson Unit AOU Careggi (FI)

Dr. Paolo Bongioanni
AOU Pisana, Cisanello (PI)

Full team: >8 experts in Computer Science, Biomedical Engineering, Product development